'Belgian company data plays hereditary diseases due to companies'

Gepubliceerd op 10 november 2016 om 14:52

Data from pregnant women who have to perform a narrowly-test at the Belgian company Gendia are regularly passed on to commercial enterprises.


Then respond to éventuel genetic diseases within a family by paying testing offering.According to research by BNR . The medical company performs many Dutch pregnant women from the sipping test.

Women must fill out a form required for the test.
If they have indicated herein that cancer occurs in the family, they are then months and sometimes years approached for a preventive cancer screening, which costs 359 euros.

According to the European privacy legislation use of personal medical data for commercial purposes is prohibited without the explicit permission given there for.

Commenting on BNR late director Patrick Willems Gendia know that there is no violation of privacy. According to him, it is his duty as a clinical geneticist to identify women at risk and the cancer test.

The Dutch Federation of Patients is not pleased with the recruitment. Across the BNR is dismissed as "highly inappropriate and 'rare blame. According to the federation of people are made unnecessarily frightened and hunted costs.

The narrowly-test allows for non-invasive prenatal test. By means of the test can, inter alia, Down's syndrome are detected early.

By Editors AD: Photo: Reuters

Reactie plaatsen


Er zijn geen reacties geplaatst.